Close
Close

Gangliosidosis GM1 type 3

Overview

A rare biochemical disorder involving a deficiency of an enzyme (beta-galactosidase A) which results in the accumulation of harmful chemicals (GM1 gangliosides) in the central nervous system and other body tissues. Type III involves a lesser degree of accumulation than type II or I.

Symptoms - Gangliosidosis GM1 type 3

* Gait ataxia * Dysarthria * Spasticity * Progressive dystonia * Mild mental impairment

Causes - Gangliosidosis GM1 type 3

Not supplied.

Prevention - Gangliosidosis GM1 type 3

Not supplied.

Diagnosis - Gangliosidosis GM1 type 3

enzyme assay

Prognosis - Gangliosidosis GM1 type 3

Enzyme deficiency results in accumulation of GM1 gangliosides in the central nervous system (especially the basal ganglia) and galactosyl oligosaccharides. Keratan-sulfate degradation products accumulate in somatic cells (visera). With type III, the deposition of GM1 gangliosides is less extensive than with the other two types. Deposition of substances in the peripheral tissues is also less extensive in type III (than in I and II).

Treatment - Gangliosidosis GM1 type 3

no disease-specific treatment available

Resources - Gangliosidosis GM1 type 3

Not supplied.
Videos
Currently no videos.
To submit one, CLICK HERE
Clinical Trials
No clinical trial found
Research Publications